3. Essential Thrombocythemia

Essential thrombocythemia

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000. The median age at diagnosis is 65 to 70 years, but the disease may occur at any age. The female to male ratio is about 2:1. The clinical pictu...

Ruxolitinib for essential thrombocythemia?

Thrombospondin in essential thrombocythemia.

Essential thrombocythemia is a myeloproliferative disorder characterized by frequent bleeding and thrombotic complications. On a molecular level, two abnormalities of platelet thrombospondin have been identified: abnormal glycosylation of the intact 185,000-dalton chain has been detected and a shortened form of the thrombospondin chain is present. We have used two monoclonal antibodies and Lens...

Essential thrombocythemia and pregnancy.

+39.79.228375. Fax. international +39.79.228282. Received January 17, 1995; accepted February 27, 1995. Sir, the management of essential thrombocythemia (ET) in young patients is still controversial and represents an intriguing problem especially, during pregnancy. We have read with interest the article by Radaelli et al., which reports a concise review of published data on the course of pregna...

Management of essential thrombocythemia.

Essential thrombocythemia (ET) is a Philadelphia chromosome (Ph)-negative myeloproliferative neoplasm (MPN) characterized by thrombocytosis and megakaryocytic hyperplasia of the bone marrow, with presence of the JAK2 V617F mutation in 50%-60% of patients. ET evolves to myelofibrosis in a minority of cases, whereas transformation to acute leukemia is rare and increases in association with the us...